TATX-21

TATX-21 is a **preclinical rabbit-derived anti-ALK1 monoclonal antibody program** being developed by ImmunoPrecise Antibodies through its Talem Therapeutics subsidiary. The program comprises a diverse panel of monoclonal antibodies generated from rabbit B cells using single B cell discovery technology and is directed against **activin receptor-like kinase 1**. Available sources describe TATX-21 as targeting ALK1 and in at least one source as an **ALK1 agonist**; it has also been associated with **anti-angiogenic effects** and proposed development in **solid tumors**, while broader anti-ALK1 antibody research cited alongside the program discusses potential use in **atherosclerotic cardiovascular disease** through inhibition of LDL-mediated transcytosis. The asset remains investigational with no identified brand name and no disclosed clinical-stage administration or formulation details.

Other names

anti-ALK1 rabbit-derived monoclonal antibody panelanti-ALK-1 rabbit-derived monoclonal antibody panelanti-ALK 1 rabbit-derived monoclonal antibody panel